DVLT Vivasor Filing: Ownership Signal or Selling Pressure?
A filing-backed DVLT update explaining Vivasor's Form 3 initial position, Form 4 20M-share sale, Schedule 13G remaining stake, and the proof gate investors should monitor.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
20Results7Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
DVLT June 2026 deep dive: the $2B headline is not the thesis yet
A filing-led Datavault AI deep dive covering Q1 2026 results, product architecture, RWA tokenization, SanQtum GPU infrastructure, NYIAX/CyberCatch/DelivMeds optionality, HELMEX structured financing, dilution, and the proof gates that matter next.
OpenDatavault AI Inc. (DVLT)
SEC filings, financial facts, source resources, and Goglides workspace context for Datavault AI Inc..
OpenDVLT's $2B term sheet: financing breakthrough or dilution trap?
Datavault AI's $2.0B structured financing term sheet could give the company a collateral base and global tokenization mandate, but the deal is non-binding, potentially dilutive, and loaded with proof gates.
OpenDVLT $2B structured financing explained for beginners
A beginner-friendly translation of Datavault AI's $2.0B structured financing term sheet, including term sheet status, dilution, tranches, the $25M payment, share-value math, and shareholder proof gates.
OpenDVLT Q1 2026 update: contract story is bigger, cash proof is still the test
A filing-led Datavault AI Q1 2026 earnings thesis focused on recognized revenue, tokenization contracts, cash conversion, losses, liquidity, and dilution risk.
OpenDVLT's product story is getting bigger. The revenue proof is still thin.
A product-level DVLT diligence addendum that maps VerifyU, ADIO, Datavault, IDE, RWA, and NILX against audited revenue proof, cash conversion, and customer validation.
OpenDVLT's $328M RWA exchange deal: breakthrough or proof gate?
Datavault AI's Perpetuals.com agreement gives its RWA tokenization story a needed liquidity layer, but the investment case still depends on listings, trading volume, fee recognition, and cash collection.
OpenDVLT institutional flow check: financing signal, not a supply-crunch thesis
A source-backed Datavault AI analysis that separates the real May 2026 institutional financing signal from unsupported dark-pool, hedge-fund, bank-upgrade, and supply-crunch claims.
OpenDVLT $2B HELMEX Mystery: Is the Address Really the Red Flag?
A beginner-friendly, fact-based DVLT brief on HELMEX, the UK address controversy, the non-binding $2B term sheet, the $25M payment, dilution, and board rights.
OpenDVLT's next test: cash collection, dilution, and real customer proof
A filing-led diligence review of Datavault AI, focused on revenue quality, cash conversion, dilution, tokenization claims, GPU deployment proof, and validation gates.
OpenDatavault AI: platform ambition, cash proof missing
A Coverage Bootstrap Datavault AI company evaluation covering data monetization, credentialing, ADIO, RWA tokenization, exchange infrastructure, customer concentration, related-party revenue, dilution, and cash-conversion proof.
OpenDVLT bull case: AI data ownership infrastructure
A highly bullish but source-gated Datavault AI analysis framing DVLT as a speculative public option on AI data ownership, tokenization, SanQtum edge infrastructure, CyberCatch optionality, and contract-to-cash proof gates.
OpenDVLT 8-K: $2B headline, $25M cash test
Datavault AI's June 4 Form 8-K turns the structured financing story into a cash, dilution, control, and approval proof gate.
OpenAethlon Medical: the blood-filter high-risk thesis racing a $7 million cash clock
AEMD is not a revenue story yet. It is a clinical-stage Hemopurifier bet with FDA Breakthrough Device designations, an Australian oncology trial, a going-concern warning, reverse splits, warrant mechanics and a cash balance that makes every new data point matt
OpenAdaptive Biotechnologies: Can clonoSEQ outrun the cash-burn clock?
Adaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenADC Therapeutics: the lymphoma readout trying to beat the royalty wall
ADCT already sells ZYNLONTA, but the story is not solved by having revenue. The next question is whether the 2026 lymphoma data can widen the drug's role before cash burn, royalties, debt, and dilution take the lead.
OpenAdagene: the masked-antibody bet trying to outrun dilution
Adagene is trying to turn SAFEbody antibody masking into a broader immuno-oncology platform. The hook is muzastotug's early dose-dependent signal; the catch is that randomized proof, partner execution, and financing still decide the stock.
OpenActuate Therapeutics: the survival signal with a July cash wall
Actuate has a company-defining elraglusib Phase 2 pancreatic-cancer survival signal and a new oral IND, but the same source set shows no product revenue, going-concern disclosure, and a need for capital beyond July 2026.
OpenAscentage Pharma (AAPG) Coverage Bootstrap: commercial-stage oncology biotech with China approvals and global Phase 3 optionality
Official-source baseline for Ascentage Pharma using SEC submissions, FY2025 Form 20-F, SEC companyfacts, company-filed FY2025 results releases, ASCO 2026 update, annual meeting materials, and oncology peer filings.
Open